Navigation Links
Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
Date:11/5/2008

SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- On Friday, November 7, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC) (MTA: CTIC) management team will host a quarterly conference call to discuss the Company's 2008 third quarter achievements and financial results.

Conference Call Numbers

Friday, November 7

8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time

1-877-835-3299 (US Participants)

1-303-262-2078 (International)

Call-back numbers for post-listening available at 11:30 a.m. Eastern:

1-800-405-2236 (US Participants)

1-303-590-3000 (International)

Passcode: 11121525#

Live audio webcast at http://www.celltherapeutics.com will be archived for post listening approximately two hours after call ends.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

F: 206.272.4434

E: media@ctiseattle.com

http://www.celltherapeutics.com/press_room

Investors Contact:

Ed Bell

T: 206.282.7100

Lindsey Jesch Logan

T: 206.272.4347

F: 206.272.4434

E: invest@ctiseattle.com

http://www.celltherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
2. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
4. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
6. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
7. Cell Therapeutics, Inc. Announces Reverse Stock Split
8. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
11. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... A luxury car manufacturer ... popular corporate team building events this summer. , Each team gathered ... competition to whet their palettes. Three teams were then formed, and each ...
(Date:7/27/2017)... RESEARCH TRIANGLE PARK, N.C., July 27, 2017 ... today announced its financial results for the second ... "Our second quarter total net revenues ... level ever," said Martine Rothblatt, Ph.D., United Therapeutics ... believe that Orenitram is well-positioned given the large ...
(Date:7/26/2017)... ... 2017 , ... CardioWise, Inc. , is pleased to ... analysis software, and an associated pending patent from Johns Hopkins Technology Ventures through ... uses high resolution cardiac CT to analyze cardiac wall motion that provides extraordinary ...
(Date:7/26/2017)... ... July 26, 2017 , ... Franz ... Semantic Graph Database technology for Knowledge Graphs, today announced Gruff v7.0 , ... Gruff provides novice users and graph experts the ability to visually build queries ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):